8-K: Axsome Therapeutics Reports Strong 2024 Financial Results and Advances Pipeline

Axsome Therapeutics announces positive financial results for 2024, driven by strong commercial growth and pipeline advancements, including FDA approval of Symbravo and progress in clinical trials.

Summary

• Axsome Therapeutics reported its fourth quarter and full year 2024 financial results, highlighting significant revenue growth and pipeline progress.
• Total net product revenues for 4Q 2024 were $118.8 million, and $385.7 million for the full year, representing year-over-year growth of 66% and 88%, respectively.
• Auvelity net product sales were $92.6 million for 4Q 2024 and $291.4 million for the full year, showing year-over-year growth of 89% and 124%, respectively.
• Sunosi net product revenues were $26.2 million for 4Q 2024 and $94.3 million for the full year, representing year-over-year growth of 16% and 26%, respectively.
• The company's net loss for 4Q 2024 was $74.9 million, or $(1.54) per share, and for the full year, it was $287.2 million, or $(5.99) per share.
• Cash and cash equivalents totaled $315.4 million as of December 31, 2024.
• Axsome believes its current cash is sufficient to fund anticipated operations into cash flow positivity.
• The FDA approved Symbravo for acute migraine treatment in January 2025, with commercial availability expected in approximately four months.
• NDA submissions for AXS-05 in Alzheimers disease agitation and AXS-12 in narcolepsy are anticipated in the second half of 2025.
• Topline results from Phase 3 trials of solriamfetol in ADHD and MDD, and Symbravo in migraine are expected in 1Q 2025.
• A pivotal Phase 2/3 trial of AXS-05 in smoking cessation is planned for initiation in 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial performance, regulatory approvals, and pipeline advancements. While there are some negatives like net losses and trial delays, the overall tone is optimistic and suggests potential for future growth.

Positives

• Significant revenue growth driven by Auvelity and Sunosi.
• FDA approval of Symbravo expands the commercial portfolio.
• Advancement of the pipeline with successful completion of Phase 3 trials for AXS-05 in Alzheimers disease agitation and AXS-12 in narcolepsy.
• Anticipated NDA submissions for AXS-05 and AXS-12 in the second half of 2025.
• Strong payer coverage for Auvelity and Sunosi.
• Settlement of patent litigation related to Auvelity provides clarity on market exclusivity.
• Current cash position is expected to fund operations into cash flow positivity.

Negatives

• The company reported a net loss of $74.9 million for 4Q 2024 and $287.2 million for the full year.
• Increased R&D and SG&A expenses contributed to the net loss.
• The ENGAGE Phase 3 trial of solriamfetol in BED now anticipates topline results in 2026, a delay from previous expectations.

Risks

• The commercial success of Sunosi, Auvelity, and Symbravo is subject to market acceptance and competition.
• The company's ability to obtain regulatory approval for its product candidates is not guaranteed.
• Clinical trial results may not be indicative of final results.
• The company's intellectual property rights may be challenged.
• Unforeseen circumstances or disruptions to normal business operations could impact results.
• The company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales is a risk.

Future Outlook

Axsome anticipates multiple value-driving catalysts ahead, including new product/indication launches through 2027 and Phase 3 topline data readouts through 2026. The company expects its current cash to fund operations into cash flow positivity.

Management Comments

• 2024 was another defining year for Axsome, driven by strong commercial growth and a rapidly advancing late-stage pipeline, which culminated in the successful completion of our Phase 3 clinical program for AXS-05 in Alzheimers disease agitation, and most recently, the U.S. approval of Symbravo last month for the acute treatment of migraine with or without aura in adults, said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.
• With potentially five marketed products across six CNS indications of great unmet need over the next 12-18 months, we are well positioned to continue delivering innovative new medicines to patients, and significant nearand long-term value to shareholders.

Industry Context

Axsome is operating in the central nervous system (CNS) therapeutics market, which addresses a broad range of psychiatric and neurological conditions. The company's focus on novel mechanisms of action and differentiated products positions it to compete effectively in this space. The approval of Symbravo and the advancement of its pipeline programs demonstrate its commitment to addressing unmet needs in CNS disorders.

Comparison to Industry Standards

• Axsome's revenue growth for Auvelity at 124% year-over-year is strong compared to other recent antidepressant launches, suggesting a successful market penetration.
• The company's focus on CNS disorders aligns with the industry's increasing attention to mental health and neurological conditions.
• Competitors in the antidepressant market include companies like Eli Lilly (Prozac, Cymbalta) and Pfizer (Zoloft), while companies like Teva and Amgen compete in the migraine treatment space.
• Axsome's pipeline, including AXS-05 and AXS-12, targets areas with significant unmet needs, potentially offering differentiated treatments compared to existing options.

Stakeholder Impact

• Shareholders can expect potential value appreciation from pipeline advancements and commercial success.
• Patients will benefit from new treatment options for CNS disorders.
• Employees may experience growth opportunities within the company.
• Payers will need to consider coverage for new and existing Axsome products.

Next Steps

• Submit NDA for AXS-14 in fibromyalgia (1Q 2025).
• Report topline results from Phase 3 EMERGE trial of AXS-07 in migraine (1Q 2025).
• Report topline results from Phase 3 FOCUS trial of solriamfetol in ADHD (1Q 2025).
• Report topline results from Phase 3 PARADIGM trial of solriamfetol in MDD (1Q 2025).
• Initiate Phase 2/3 trial of AXS-05 in smoking cessation (2025).
• Submit NDAs for AXS-05 in Alzheimers disease agitation and AXS-12 in narcolepsy (2H 2025).
• Report topline results from Phase 3 ENGAGE trial of solriamfetol in binge eating disorder (2026).
• Report topline results from Phase 3 SUSTAIN trial of solriamfetol in shift work disorder (2026).

Key Dates

Keywords

Axsome Therapeutics, Financial Results, Auvelity, Sunosi, Symbravo, Clinical Trials, NDA Submission, Alzheimers Disease Agitation, Narcolepsy, ADHD, MDD, Binge Eating Disorder, Shift Work Disorder, Migraine